IXAZOMIB CITRATE

Search structure
Trade Names:
Synonyms:
Status: Approved (2015)
Entry Type: Small molecule
Molecule Category: Salt Prodrug
UNII: 46CWK97Z3K
Parent Compound: IXAZOMIB

Structure
InChI Key MBOMYENWWXQSNW-AWEZNQCLSA-N
Smile CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(=O)O)(CC(=O)O)O1
InChI
InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-19(32)20(34-21,7-16(27)28)8-17(29)30)25-15(26)9-24-18(31)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,31)(H,25,26)(H,27,28)(H,29,30)/t14-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C20H23BCl2N2O9
Molecular Weight 517.13
AlogP None
Hydrogen Bond Acceptor None
Hydrogen Bond Donor None
Number of Rotational Bond None
Polar Surface Area None
Molecular species None
Aromatic Rings None
Heavy Atoms None

Pharmacology

Action Mechanism of Action Reference
INHIBITOR 26S proteosome inhibitor DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 4 D009369 ClinicalTrials
Leukemia, Plasma Cell 2 D007952 ClinicalTrials
Plasmacytoma 2 D010954 ClinicalTrials
Lymphoma 2 D008223 ClinicalTrials
Lymphoma, Mantle-Cell 2 D020522 ClinicalTrials
Waldenstrom Macroglobulinemia 2 D008258 ClinicalTrials
Sarcoma, Kaposi 2 D012514 ClinicalTrials
Graft vs Host Disease 2 D006086 ClinicalTrials
Amyloidosis, Familial 1 D028226 ClinicalTrials
Leukemia, Myeloid, Acute 1 D015470 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 D054198 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 D054198 ClinicalTrials
Breast Neoplasms 1 D001943 ClinicalTrials
Glioblastoma 0 D005909 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
13.94
Gastrointestinal disorders
12.77
Infections and infestations
9.45
Respiratory, thoracic and mediastinal disorders
7.95
Blood and lymphatic system disorders
7.46
Nervous system disorders
6.3
Investigations
5.99
Injury, poisoning and procedural complications
5.64
Skin and subcutaneous tissue disorders
4.73
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
3.58
Cardiac disorders
3.54
Vascular disorders
3.38
Musculoskeletal and connective tissue disorders
3.32
Metabolism and nutrition disorders
3.3
Renal and urinary disorders
2.43

Cross References

Resources Reference
ChEBI 90939
ChEMBL CHEMBL3545432
FDA SRS 46CWK97Z3K
PubChem 56844015
SureChEMBL SCHEMBL4427479
ZINC ZINC000200299610
CONTENTS